8月4日，华润医疗(01515)盘中下跌8.35%，截至09:30，报4.06元/股，成交1651.07万元。 本文源自：金融界 作者：行情君 华润医疗控股有限公司是内地和香港两地规模领先的医疗上市公司，致力于专业化整合和资本化运作医 疗资源，其经营的医疗机构多达146家，运营床位数超过21985张。公司在2023年收购了母公司华润健康 的36家优质医疗机构，增强了医疗服务能力，并对集团化运营和精细化管理模式进行创新改良，以满足 人民群众的多样化医疗健康服务需求。 截至2024年年报，华润医疗营业总收入98.55亿元、净利润5.66亿元。 ...

公告称，预期利润下降主要由于医保次均费用下降导致成员医疗机构经营利润下降。同时公司逐渐退出 IOT(即投资-运营-移交模式)业务，其对应的利润贡献下降。2025年下半年公司将继续积极改善收入结 构，推动管理精细化，控制运营成本，提高经营效益。 智通财经APP获悉，华润医疗(01515)盈警后低开7%，截至发稿，跌7%，报4.12港元，成交额415.91万 港元。 消息面上，8月4日，华润医疗发布公告，公司预料截至2025年6月30日止六个月的公司拥有人应占利润 相较2024年同期下降约20%至25%；而经剔除有关集团一次性收到燕化IOT协议下以前年度管理费及供 应链损失赔偿款项约人民币2.1亿元和对应的企业所得税后，公司拥有人应占利润相较 2024年同期下降 约55%至60%。 ...

Core Viewpoint - China Resources Medical (01515) issued a profit warning, anticipating a profit decline of approximately 20% to 25% for the six months ending June 30, 2025, compared to the same period in 2024, with a more significant decline of about 55% to 60% when excluding one-time management fees and compensation related to the Yanhua IOT agreement [1][1][1] Group 1 - The company's stock opened lower by 7% and is currently trading at HKD 4.12, with a trading volume of HKD 4.1591 million [1][1] - The anticipated profit decline is primarily attributed to a decrease in average medical expenses under the medical insurance system, leading to reduced operating profits for member medical institutions [1][1][1] - The company is gradually exiting the IOT (Investment-Operation-Transfer) business, resulting in a decline in profit contributions from this segment [1][1][1] Group 2 - For the second half of 2025, the company plans to actively improve its revenue structure, enhance management precision, control operational costs, and increase operational efficiency [1][1][1]

Core Viewpoint - China Resources Medical expects a decline in profit attributable to shareholders by 20% to 25% for the six months ending June 30, 2025, primarily due to reduced average medical expenses under the healthcare insurance system and a gradual exit from the IOT (Investment-Operation-Transfer) business [1] Financial Summary - The profit attributable to shareholders is projected to decline by 55% to 60% when excluding a one-time gain of approximately 210 million RMB from the Yan Hua IOT agreement, which includes management fees and compensation for supply chain losses [1] - The main reason for the profit decline is the decrease in operating profit of its medical institutions due to lower average medical expenses [1] Business Strategy - The company plans to optimize its revenue structure, enhance management efficiency, and control costs in the second half of 2025 to improve operational effectiveness [1]

Core Viewpoint - China Resources Medical (01515) anticipates a decline in profit attributable to shareholders for the six months ending June 30, 2025, by approximately 20% to 25% compared to the same period in 2024, with a more significant drop of about 55% to 60% when excluding one-time management fees and compensation related to the Yanhua IOT agreement totaling approximately RMB 210 million [1] Financial Performance - The expected profit decline is primarily due to a decrease in average medical expenses under the healthcare insurance system, leading to reduced operating profits for member medical institutions [1] - The company is gradually exiting the IOT (Investment-Operation-Transfer) business, resulting in a corresponding decrease in profit contribution from this segment [1] Future Outlook - In the second half of 2025, the company plans to actively improve its revenue structure, promote refined management, control operating costs, and enhance operational efficiency [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限責任公司） （股份代號：1515） 盈利預警 本公告由華潤醫療控股有限公司（「本公司」，連同其子公司統稱為「本集團」）乃根 據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09 (2) (a)條及香港法 例第571章證券及期貨條例第XIVA部的內幕消息條文（ 定義見上市規則 ）作出。 茲提述本公司日期為2025年2月21日的公告（「該公告」），內容有關燕化IOT協議爭 議的最新進展。除文義另有所指外，本公告所用詞彙與該公告所界定者具有相同 涵義。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者， 本公司正在 編製其截至2025年6 月30日止 六個月（「報告期」）之綜合 業績。根據目 前已有資料並對本集團未經審計的報告期綜合管理賬目作出初步評估，本公司預 料報告期的本公 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 華潤醫療控股有限公司 呈交日期: 2025年8月1日 本月底法定/註冊股本總額： HKD 760,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01515 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 1,296,676,516 | | 0 | | 1,296,676,516 | | 增加 / 減少 (-) | | | | | | | | | | 本月底結存 | | | | 1,296,676,51 ...

内容概要：吻合器是现代手术中不可或缺的高值耗材，是医学上使用的替代手工缝合的设备，近年来， 随着我国微创外科手术数量逐步增加，医生对吻合操作的稳定性、便捷性、临床预后等需求逐步提高， 电动腔镜吻合器应运而生，近年来，随着我国人口老龄化程度不断加深、国民对医疗服务的质量和效果 要求越来越高，微创手术逐渐成为手术治疗的主流趋势，随着微创手术量的不断增加，腔镜吻合器市场 需求也与日俱增，电动腔镜吻合器能够提高手术的精准性和安全性，减少术后并发症，更好地满足患者 和医生对微创手术的需求，因此，更受医生和患者的欢迎，2024年，随着一系列医疗器械集中采购政策 全面落地实施，对我国电动腔镜吻合器行业发展产生了深刻的影响，一方面使电动腔镜吻合器的需求及 接纳程度明显提升，另一方面，受集采降价影响我国电动腔镜吻合器行业市场规模有所下滑，据统计， 2024年我国电动腔镜吻合器行业市场规模降至37.2亿元，同比减少7.38%。 上市企业：戴维医疗（300314）、迈瑞医疗（300760）、莲池医院（831672.NQ）、华润医疗 （01515.HK） 相关企业：强生（苏州）医疗器材有限公司、江苏风和医疗器材股份有限公司、宁波维尔 ...

Financial Performance - In 2024, the Group achieved operating revenue of RMB 9.855 billion, representing a year-on-year decrease of 2.5%[20] - The net profit attributable to the parent amounted to RMB 566 million, reflecting a year-on-year increase of 119.6%[20] - In 2024, the consolidated revenue of China Resources Medical amounted to RMB 9.855 billion, a decrease from RMB 10.108 billion in FY2023, while the consolidated net profit increased to RMB 672 million from RMB 328 million in FY2023[37] - The Group's net profit for the reporting period was RMB 672 million, representing a year-on-year increase of 104.9%[72] - The revenue from the hospital business segment for 2024 was RMB 9,185 million, representing a year-on-year decrease of 2.4%[55] - Revenue from other business was RMB 670 million, a year-on-year decrease of 4.5%, mainly due to restructuring of supply chain services[57] - The profit of the hospital business segment recorded RMB 766 million, representing a year-on-year increase of 20.1%[56] Operational Metrics - The number of conventional out-patient visits increased to 10.32 million, a year-on-year growth of 1.9%[20] - The number of in-patient visits rose to 0.56 million, representing a year-on-year increase of 1.0%[20] - The number of outpatient visits and inpatient visits for the Group's self-owned hospitals increased by 1.3% and 1.0% year-on-year, respectively, with approximately 10.32 million outpatient visits and 560,000 inpatient visits recorded[36][38] - Out-patient visits increased by 1.3% to 10,325,639, while in-patient visits increased by 1.0% to 560,149[55] Dividends and Shareholder Returns - The Group proposed a dividend of RMB 0.132 per share for 2024, with an interim dividend of RMB 0.05 already distributed and a final dividend of RMB 0.082 proposed[20] - The proposed final dividend for FY2024 is RMB8.2 cents per share, an increase from RMB6 cents per share in FY2023[142] - The total amount of dividend for FY2024 is approximately RMB171 million, with RMB65 million paid as interim dividend and RMB106 million proposed as final dividend[142] - The Group's ability to pay dividends depends on its financial condition, current and future operations, liquidity position, and capital requirements[147] Strategic Focus and Future Plans - The Group aims to deepen structural reforms and improve quality and efficiency in 2025, focusing on core competencies such as discipline construction and digital intelligence[26][30] - The Group aims to strengthen its core competencies in 2025, focusing on discipline construction, patient services, and digital intelligence[105] - The year 2025 marks the conclusion of the "14th Five-Year Plan" and the planning phase for the "15th Five-Year Plan," with a focus on improving quality and efficiency[106] - The Group plans to leverage its state-owned enterprise status to achieve high-quality development and fulfill social responsibilities while enhancing market value management[29][30] Employee and Operational Management - As of December 31, 2024, the Group had a total of 19,953 full-time employees, a decrease from 20,172 employees as of December 31, 2023[95] - For FY2024, the staff cost was approximately RMB 3,470 million, compared to RMB 3,406 million in FY2023, reflecting an increase of about 1.9%[95] - The Group emphasizes the importance of employee safety and development, implementing high standards of health and safety measures[139] Compliance and Governance - The Group has complied with all relevant PRC laws and regulations regarding environmental protection during the year ended December 31, 2024[123] - The Group has established a Supplier Code of Conduct to ensure compliance with local regulations governing labor, health, safety, and the environment[138] - All independent non-executive Directors confirmed their independence and compliance with the Listing Rules during the reporting period[190][193] Investments and Acquisitions - The Group did not have any significant acquisitions or disposals during the reporting period, except for investments in associates[58] - As of December 31, 2024, the Group's investment in JR Holdings and JR Renkang amounted to RMB 874 million and RMB 2.45 million, respectively[63] - JR Holdings and JR Renkang achieved a combined revenue of RMB 373 million, resulting in a net profit of RMB 200 million during the reporting period[64] Customer and Supplier Relations - The Group's five largest customers accounted for approximately 5.1% of total sales in 2024, down from 6.5% in 2023, with the largest customer contributing about 1.5% of total sales, down from 3.0%[168][173] - Purchases from the Group's five largest suppliers represented approximately 12.1% of total purchases in 2024, a decrease from 15.7% in 2023, with the largest supplier accounting for about 2.8% of total purchases, down from 4.6%[169][173]

内容概要：近年来，我国高度重视医疗事业发展，积极推动医疗体制改革，我国不论医疗机构数量还是 医疗服务水平均显著提升，据国家统计局数据显示，2024年我国医院数量达39000个，同比增长 1.68%，与此同时，我国政府鼓励社会资本参与医疗服务领域，促进了多元化医疗服务体系的形成，为 医院经营管理带来了更多的创新机遇和发展空间，据统计，2024年我国医院经营管理行业市场规模达 8062.8亿元，同比增长9.53%。 上市企业：爱尔眼科（300015）、九州通（600998）、通策医疗（600763）、华润医疗 （01515.HK）、润华服务（02455.HK）、新里程（002219）、国药控股（01099.HK） 相关企业：中国医学科学院北京协和医院、四川大学华西医院、上海复医天健医疗服务产业股份有限公 司、国药诺达智慧后勤服务（上海）有限公司、上海益中亘泰（集团）股份有限公司、上海吉晨卫生后 勤服务管理有限公司、爱玛客服务产业（中国）有限公司 关键词：医院经营管理发展背景、医院经营管理产业链、医院经营管理市场规模、医院经营管理竞争格 局、医院经营管理发展趋势 一、概述 医院是指以向人提供医疗护理服务为主要目的的 ...